ESMO

Keytruda Plus Herceptin, Chemo Boosts PFS in HER2+ Gastric/GEJ Cancer

October 28th 2023, 5:00pm

Article

Keytruda plus the combination of Herceptin and chemotherapy led to an improvement in progression-free survival versus placebo plus Herceptin and chemotherapy in the first-line treatment of some patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

Pluvicto Plus Xtandi Enhances Anti-Tumor Activity for Some Patients With Prostate Cancer

October 27th 2023, 9:00pm

Article

Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.

Imfinzi-Chemo Combo Shows Promise in Ongoing Gastric Cancer Trial

October 27th 2023, 1:00pm

Article

The addition of Imfinzi to a chemotherapy regimen called FLOT tended to boost pathologic complete response rates in patients with gastric or gastroesophageal junction cancer.

Keytruda Plus Chemo Improves Progression-Free Survival in Cervical Cancer

October 25th 2023, 10:00pm

Article

The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Verzenio, Endocrine Therapy Boosts Outcomes in High-Risk Breast Cancer

October 25th 2023, 3:00pm

Article

Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.

Cabometyx Improves Survival Without Progression in Previously Treated Advanced NETs

October 24th 2023, 11:00pm

Article

Patients with previously treated advanced neuroendocrine tumors who received treatment with Cabometyx had improved progression-free survival compared with placebo.

Rybrevant-Leclaza Combo Outperforms Tagrisso in EGFR-Mutant Advanced NSCLC

October 24th 2023, 3:00pm

Article

Patients with advanced non-small cell lung cancer with an EGFR mutation had a greater risk reduction for disease progression with frontline Rybrevant plus Leclaza compared with Tagrisso alone.

Enhertu Shows Survival Improvements For Patients With Mestastatic Breast Cancer

October 24th 2023, 1:00pm

Article

Central nervous system progression-free survival was shown to improve with Enhertu than with alternative treatments for patients with HER2-positive metastatic breast cancer and brain metastases.

Presurgical Keytruda Plus Chemotherapy Improves Response for Some With Breast Cancer

October 23rd 2023, 10:00pm

Article

Neoadjuvant Keytruda plus chemotherapy followed by adjuvant Keytruda plus endocrine therapy generated a statistically significant increase in pathologic complete response compared to pre-surgical placebo and chemotherapy followed by adjuvant Keytruda and endocrine therapy for patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Pluvicto Improves Survival Without Progression in Certain Patients With Prostate Cancer

October 23rd 2023, 9:00pm

Article

Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto.